OTTMUSG00000005931 Inhibitors
Chemical inhibitors of Germ Cell-Specific Gene 1-Like Protein 2 precursor (Gsg1l2) employ various mechanisms to effectively inhibit this protein and disrupt its cellular function. Acalabrutinib, a direct inhibitor, acts by binding to the kinase domain of Gsg1l2, disrupting its enzymatic activity. This binding prevents Gsg1l2 from phosphorylating its downstream substrates and initiating signaling events, ultimately leading to the functional inhibition of Gsg1l2 within the cell. Selumetinib, another direct inhibitor, targets the MEK pathway, which is a critical component of Gsg1l2's signaling cascade. By inhibiting MEK, Selumetinib disrupts the downstream signaling triggered by Gsg1l2, effectively inhibiting the protein's function. Wortmannin, a direct inhibitor as well, interferes with the phosphoinositide 3-kinase (PI3K) pathway, an essential pathway for Gsg1l2's function. This disruption at the pathway level results in the functional inhibition of Gsg1l2 within the cellular context. Sunitinib, Gefitinib, and other direct inhibitors act similarly, employing distinct mechanisms to target various aspects of Gsg1l2's function.
Rapamycin, while not a direct inhibitor, achieves functional inhibition of Gsg1l2 indirectly by targeting the mTOR pathway upstream of Gsg1l2's signaling cascade. This disruption cascades down to inhibit Gsg1l2's function, contributing to the overall functional inhibition of the protein. The diverse mechanisms employed by these chemical inhibitors provide researchers with valuable tools for investigating the specific roles of Gsg1l2 within cellular processes, offering insights into potential avenues for further scientific exploration.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib directly inhibits Gsg1l2 by binding to its kinase domain, disrupting its enzymatic activity and downstream signaling. This results in functional inhibition of Gsg1l2. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a direct inhibitor of Gsg1l2. It targets the MEK pathway within the protein's signaling cascade, leading to the disruption of Gsg1l2's function and functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin directly inhibits Gsg1l2 through its interference with the phosphoinositide 3-kinase (PI3K) pathway, which is essential for the protein's function. This leads to functional inhibition. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Sunitinib is a direct inhibitor of Gsg1l2. It hinders the kinase activity of the protein, disrupting phosphorylation events and downstream signaling, ultimately resulting in functional inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib directly inhibits Gsg1l2 by targeting its kinase domain, thereby interfering with its enzymatic activity and causing functional inhibition of Gsg1l2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a direct inhibitor of Gsg1l2. It acts by disrupting proteasome activity, leading to the accumulation of misfolded proteins and the functional inhibition of Gsg1l2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin indirectly inhibits Gsg1l2 by targeting the mTOR pathway, which is upstream of the protein's signaling. This disruption cascades down to inhibit the function of Gsg1l2, leading to functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 directly inhibits Gsg1l2 by interfering with the MEK pathway within the protein's signaling cascade. This disruption results in the functional inhibition of Gsg1l2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 directly inhibits Gsg1l2 by targeting phosphoinositide 3-kinase (PI3K), a crucial component of the protein's signaling. This chemical disruption leads to the functional inhibition of Gsg1l2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 directly inhibits Gsg1l2 by disrupting the extracellular signal-regulated kinase (ERK) pathway, which is involved in the protein's signaling. This leads to the disruption of Gsg1l2's function and functional inhibition. | ||||||